Generation Investment Management LLP Invests $728.17 Million in West Pharmaceutical Services, Inc. $WST

Generation Investment Management LLP bought a new position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund bought 2,028,322 shares of the medical instruments supplier’s stock, valued at approximately $728,168,000. West Pharmaceutical Services comprises approximately 7.1% of Generation Investment Management LLP’s investment portfolio, making the stock its 5th biggest position. Generation Investment Management LLP owned approximately 2.88% of West Pharmaceutical Services at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in the stock. Bank of Nova Scotia increased its position in West Pharmaceutical Services by 337.8% during the first quarter. Bank of Nova Scotia now owns 65,323 shares of the medical instruments supplier’s stock worth $16,373,000 after purchasing an additional 50,402 shares during the last quarter. Hsbc Holdings PLC lifted its stake in West Pharmaceutical Services by 23.3% during the fourth quarter. Hsbc Holdings PLC now owns 146,872 shares of the medical instruments supplier’s stock worth $40,425,000 after purchasing an additional 27,745 shares in the last quarter. Renaissance Technologies LLC lifted its stake in West Pharmaceutical Services by 100.2% during the 1st quarter. Renaissance Technologies LLC now owns 209,660 shares of the medical instruments supplier’s stock worth $52,549,000 after acquiring an additional 104,924 shares in the last quarter. Conestoga Capital Advisors LLC boosted its stake in shares of West Pharmaceutical Services by 6.7% in the first quarter. Conestoga Capital Advisors LLC now owns 130,970 shares of the medical instruments supplier’s stock valued at $32,826,000 after purchasing an additional 8,179 shares during the period. Finally, Comerica Bank boosted its position in West Pharmaceutical Services by 31.8% in the 4th quarter. Comerica Bank now owns 56,693 shares of the medical instruments supplier’s stock valued at $15,599,000 after buying an additional 13,680 shares during the period. 93.90% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages have recently commented on WST. Citigroup boosted their price objective on West Pharmaceutical Services from $400.00 to $412.00 and gave the stock a “buy” rating in a research report on Monday, August 3rd. Weiss Ratings raised West Pharmaceutical Services from a “hold (c)” rating to a “hold (c+)” rating in a report on Friday, August 7th. KeyCorp raised their price objective on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “overweight” rating in a research report on Thursday, July 2nd. Evercore reissued an “outperform” rating and issued a $425.00 target price on shares of West Pharmaceutical Services in a report on Monday, July 27th. Finally, TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, West Pharmaceutical Services has an average rating of “Moderate Buy” and a consensus price target of $368.08.

West Pharmaceutical Services Price Performance

WST stock opened at $352.32 on Thursday. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.12 and a current ratio of 2.82. The firm has a market cap of $24.80 billion, a P/E ratio of 45.11, a PEG ratio of 2.42 and a beta of 1.15. West Pharmaceutical Services, Inc. has a 1 year low of $223.83 and a 1 year high of $386.00. The stock’s 50 day moving average price is $347.64 and its 200 day moving average price is $298.51.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, topping analysts’ consensus estimates of $2.08 by $0.29. The firm had revenue of $872.30 million during the quarter, compared to analysts’ expectations of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The firm’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same quarter last year, the business posted $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. On average, sell-side analysts expect that West Pharmaceutical Services, Inc. will post 8.93 earnings per share for the current fiscal year.

West Pharmaceutical Services Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, August 5th. Stockholders of record on Wednesday, July 29th were given a $0.22 dividend. The ex-dividend date of this dividend was Wednesday, July 29th. This represents a $0.88 dividend on an annualized basis and a dividend yield of 0.2%. West Pharmaceutical Services’s payout ratio is currently 11.27%.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.